> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-156/
- Published: 2017-11-12T12:00:00.000Z
- Updated: 2026-09-14T23:01:22.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140118

[**Comments Sought on Condom Labeling Info Collection**](https://www.fdaweb.com/comments-sought-on-condom-labeling-info-collection/)  
*Federal Register* notice: FDA seeks comments on an information collection for “Class II Special Controls Guidance Document: Labeling for Natural Rubber Latex Condoms — 21 CFR 884.5300.” 11/09/2017

[**Upcoming Blood Products Advisory Committee Meeting**](https://www.fdaweb.com/upcoming-blood-products-advisory-committee-meeting/)  
*Federal Register* notice: FDA announces an 11/30 to 12/1 Blood Products Advisory Committee advisory committee meeting. 11/09/2017

[**Draft Guide on Using DMF for Shared REMs Submission**](https://www.fdaweb.com/draft-guide-on-using-dmf-for-shared-rems-submission/)  
*Federal Register* notice. FDA makes available a draft guidance for industry on “Use of a Drug Master File for Shared System REMS Submissions.” 11/09/2017

[**Guide on Recurrent Herpes Labialis Drug Development**](https://www.fdaweb.com/guide-on-recurrent-herpes-labialis-drug-development-2/)  
*Federal Register* notice: FDA makes available a guidance on “Recurrent Herpes Labialis (RHL): Developing Drugs for Treatment and Prevention.” 11/08/2017

[**Proposed Info Collection on Target Product Profile Guide**](https://www.fdaweb.com/proposed-info-collection-on-target-product-profile-guide/)  
*Federal Register* notice: FDA submits to OMB a new proposed information collection supporting its “Draft Guidance for Industry and Review Staff on Target Product Profile — A Strategic Development Process Tool.” 11/08/2017

[**Comments Sought on Info Collection for Expedited Product Programs**](https://www.fdaweb.com/comments-sought-on-info-collection-for-expedited-product-programs/)  
*Federal Register* notice: FDA seeks comments on an information collection revision for its “Guidance for Industry on Expedited Programs for Serious Conditions — Drugs and Biologics OMB Control Number 0910 – 0765\. 11/08/2017

[**CDER Seeking Input on Study Data Template**](https://www.fdaweb.com/cder-seeking-input-on-study-data-template/)  
*Federal Register* notice: CDER seeks comments on a proposed “Analysis Data Reviewer’s Guide” (ADRG) template that was developed under an ongoing collaboration with the Pharmaceutical Users Software Exchange for submitting study data. 11/08/2017

[**Vitamin D Mass Spectrometry Test Put Into Class 2**](https://www.fdaweb.com/vitamin-d-mass-spectrometry-test-put-into-class-2/)  
*Federal Register* notice: FDA classifies the total 25-hydroxyvitamin D mass spectrometry test system into Class 2 (special controls). 11/07/2017

[**Class 2 for Recessive Carrier Screening Gene Mutation Detectors**](https://www.fdaweb.com/class-2-for-recessive-carrier-screening-gene-mutation-detectors/)  
*Federal Register* final order: FDA exempts from premarket notification requirements autosomal recessive carrier screening gene mutation detection systems. 11/07/2017

[**Class 2 for Health Risk Assessment Systems**](https://www.fdaweb.com/class-2-for-health-risk-assessment-systems/)  
*Federal Register* notice: FDA classifies genetic health risk assessment systems into Class 2 (special controls). 11/07/2017